Tecfidera (Biogen) effective in MS over the longterm

Data presented by Biogen IDEC show that Tecfidera (dimethyl fumarate) continues to offer consistent and strong efficacy combined with a favourable safety profile in a broad range of patients with relapsing-remitting Multiple Sclerosis (RRMS), including those patients who are newly diagnosed with the disease. These data were presented by Biogen Idec at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October. Interim analyses from the ENDORSE long-term extension study show that Tecfidera maintained its effect in reducing disease activity in patients treated for four years. No new or worsening safety signals were observed in patients who had received Tecfidera for up to six and a half years. In addition, a separate post-hoc analysis of the Phase III DEFINE and CONFIRM clinical trials shows that Tecfidera significantly reduced Multiple Sclerosis (MS) relapses in treatment-na�ve patients, while delaying the overall progression of the disease over time.